Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protagonist Therapeutics (PTGX) Income from Continuing Operations: 2017-2025

Historic Income from Continuing Operations for Protagonist Therapeutics (PTGX) over the last 8 years, with Sep 2025 value amounting to -$39.3 million.

  • Protagonist Therapeutics' Income from Continuing Operations fell 18.46% to -$39.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.9 million, marking a year-over-year decrease of 73.15%. This contributed to the annual value of $275.2 million for FY2024, which is 448.54% up from last year.
  • Latest data reveals that Protagonist Therapeutics reported Income from Continuing Operations of -$39.3 million as of Q3 2025, which was down 13.05% from -$34.8 million recorded in Q2 2025.
  • In the past 5 years, Protagonist Therapeutics' Income from Continuing Operations registered a high of $207.3 million during Q1 2024, and its lowest value of -$41.0 million during Q2 2022.
  • Moreover, its 3-year median value for Income from Continuing Operations was -$33.2 million (2024), whereas its average is $10.0 million.
  • Per our database at Business Quant, Protagonist Therapeutics' Income from Continuing Operations crashed by 335.45% in 2021 and then skyrocketed by 714.80% in 2024.
  • Protagonist Therapeutics' Income from Continuing Operations (Quarterly) stood at -$37.2 million in 2021, then rose by 7.77% to -$34.3 million in 2022, then spiked by 179.78% to $27.3 million in 2023, then surged by 381.70% to $131.7 million in 2024, then dropped by 18.46% to -$39.3 million in 2025.
  • Its Income from Continuing Operations was -$39.3 million in Q3 2025, compared to -$34.8 million in Q2 2025 and -$11.7 million in Q1 2025.